Efficacy and Safety of Dapagliflozin in Combination With Metformin in Type 2 Diabetes Patients
Primary Purpose
Type 2 Diabetes
Status
Completed
Phase
Phase 3
Locations
International
Study Type
Interventional
Intervention
dapagliflozin
glipizide
metformin hydrochloride
Sponsored by

About this trial
This is an interventional treatment trial for Type 2 Diabetes focused on measuring Dapagliflozin, efficacy, safety, metformin, Type 2 diabetes
Eligibility Criteria
Inclusion Criteria:
- Type 2 Diabetes
- Treated with oral anti-diabetic drug therapy therapy including Metformin for at least 8 weeks prior to enrolment
- HbA1c >6.5% and </=10%
Exclusion Criteria:
- Type 1 Diabetes
- Insulin therapy within one year of enrolment
- Renal (kidney) failure or dysfunction
Sites / Locations
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
1
2
Arm Description
dapagliflozin plus metformin
glipizide plus metformin
Outcomes
Primary Outcome Measures
Adjusted Mean Change in HbA1c Levels
To assess the effect of dapagliflozin plus metformin compared to glipizide plus metformin on the absolute change from baseline in HbA1c level after 52 weeks double-blind treatment in patients with type 2 diabetes who have inadequate glycaemic control on 1500 mg/day or higher doses of metformin therapy alone.
Secondary Outcome Measures
Adjusted Mean Change in Body Weight
To assess the effect of dapagliflozin plus metformin compared to glipizide plus metformin on body weight after 52 weeks double-blind treatment.
Proportion of Participants With at Least One Episode of Hypoglycemia
To assess the effect of dapagliflozin plus metformin treatment compared to glipizide plus metformin on the occurrence of hypoglycemic events. Least Squares Mean represents the percent of participants adjusted for HbA1c baseline value.
Proportion of Participants With Body Weight Reduction of at Least 5%
To evaluate the effect of dapagliflozin plus metformin compared to glipizide plus metformin on body weight assessed by a reduction after 52 weeks of at least 5% compared to baseline. Least Squares Mean represents the percent of participants adjusted for baseline value.
Full Information
NCT ID
NCT00660907
First Posted
April 15, 2008
Last Updated
March 10, 2015
Sponsor
AstraZeneca
Collaborators
Bristol-Myers Squibb
1. Study Identification
Unique Protocol Identification Number
NCT00660907
Brief Title
Efficacy and Safety of Dapagliflozin in Combination With Metformin in Type 2 Diabetes Patients
Official Title
A 52-Week International, Multi-centre, Randomised, Parallel-group, Double-blind, Active-controlled, Phase III Study With a 156-Week Extension Period to Evaluate the Efficacy and Safety of Dapagliflozin in Combination With Metformin Compared With Sulphonylurea in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycaemic Control on Metformin Therapy Alone.
Study Type
Interventional
2. Study Status
Record Verification Date
March 2015
Overall Recruitment Status
Completed
Study Start Date
March 2008 (undefined)
Primary Completion Date
December 2009 (Actual)
Study Completion Date
January 2013 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
AstraZeneca
Collaborators
Bristol-Myers Squibb
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
This study is being carried out to see if dapagliflozin as an addition to metformin is effective and safe in treating patients with type 2 diabetes when compared to glipizide (sulphonylurea) as an addition to metformin treatment.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 2 Diabetes
Keywords
Dapagliflozin, efficacy, safety, metformin, Type 2 diabetes
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
1217 (Actual)
8. Arms, Groups, and Interventions
Arm Title
1
Arm Type
Experimental
Arm Description
dapagliflozin plus metformin
Arm Title
2
Arm Type
Active Comparator
Arm Description
glipizide plus metformin
Intervention Type
Drug
Intervention Name(s)
dapagliflozin
Intervention Description
Tablet oral 2.5, 5, or 10 mg total daily dose once daily 208 weeks
Intervention Type
Drug
Intervention Name(s)
glipizide
Other Intervention Name(s)
Glucotrol
Intervention Description
Capsule oral 5, 10, or 20 mg total daily dose once or split/twice daily 208 weeks
Intervention Type
Drug
Intervention Name(s)
metformin hydrochloride
Other Intervention Name(s)
Glucophage
Intervention Description
Tablet oral 1500, 2000, or 2500 mg total daily dose split/twice daily 218 weeks
Primary Outcome Measure Information:
Title
Adjusted Mean Change in HbA1c Levels
Description
To assess the effect of dapagliflozin plus metformin compared to glipizide plus metformin on the absolute change from baseline in HbA1c level after 52 weeks double-blind treatment in patients with type 2 diabetes who have inadequate glycaemic control on 1500 mg/day or higher doses of metformin therapy alone.
Time Frame
Baseline to Week 52
Secondary Outcome Measure Information:
Title
Adjusted Mean Change in Body Weight
Description
To assess the effect of dapagliflozin plus metformin compared to glipizide plus metformin on body weight after 52 weeks double-blind treatment.
Time Frame
Baseline to Week 52
Title
Proportion of Participants With at Least One Episode of Hypoglycemia
Description
To assess the effect of dapagliflozin plus metformin treatment compared to glipizide plus metformin on the occurrence of hypoglycemic events. Least Squares Mean represents the percent of participants adjusted for HbA1c baseline value.
Time Frame
Baseline to Week 52
Title
Proportion of Participants With Body Weight Reduction of at Least 5%
Description
To evaluate the effect of dapagliflozin plus metformin compared to glipizide plus metformin on body weight assessed by a reduction after 52 weeks of at least 5% compared to baseline. Least Squares Mean represents the percent of participants adjusted for baseline value.
Time Frame
Baseline to Week 52
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Type 2 Diabetes
Treated with oral anti-diabetic drug therapy therapy including Metformin for at least 8 weeks prior to enrolment
HbA1c >6.5% and </=10%
Exclusion Criteria:
Type 1 Diabetes
Insulin therapy within one year of enrolment
Renal (kidney) failure or dysfunction
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Michael A. Nauck, Prof. Dr. med.
Organizational Affiliation
Diabeteszentrum Bad Lauterberg, Germany
Official's Role
Principal Investigator
Facility Information:
Facility Name
Research Site
City
Buenos Aires
Country
Argentina
Facility Name
Research Site
City
Caba
Country
Argentina
Facility Name
Research Site
City
Capital Federal
Country
Argentina
Facility Name
Research Site
City
Ciudad de Buenos Aires
Country
Argentina
Facility Name
Research Site
City
Corrientes
Country
Argentina
Facility Name
Research Site
City
Córdoba
Country
Argentina
Facility Name
Research Site
City
La Plata
Country
Argentina
Facility Name
Research Site
City
Rosario
Country
Argentina
Facility Name
Research Site
City
Santa Fe
Country
Argentina
Facility Name
Research Site
City
L'aigle
Country
France
Facility Name
Research Site
City
Murs Erigne
Country
France
Facility Name
Research Site
City
Nantes Cedex 1
Country
France
Facility Name
Research Site
City
Nantes
Country
France
Facility Name
Research Site
City
Paris
Country
France
Facility Name
Research Site
City
Tours
Country
France
Facility Name
Research Site
City
Vannes
Country
France
Facility Name
Research Site
City
Bad Lauterberg
Country
Germany
Facility Name
Research Site
City
Berlin
Country
Germany
Facility Name
Research Site
City
Dresden
Country
Germany
Facility Name
Research Site
City
Essen
Country
Germany
Facility Name
Research Site
City
Frankfurt
Country
Germany
Facility Name
Research Site
City
Hamburg
Country
Germany
Facility Name
Research Site
City
Heilbronn
Country
Germany
Facility Name
Research Site
City
Ludwigshafen
Country
Germany
Facility Name
Research Site
City
Mainz
Country
Germany
Facility Name
Research Site
City
Pirna
Country
Germany
Facility Name
Research Site
City
Schmiedeberg
Country
Germany
Facility Name
Research Site
City
Wangen
Country
Germany
Facility Name
Research Site
City
Perugia
Country
Italy
Facility Name
Research Site
City
Pisa
Country
Italy
Facility Name
Research Site
City
Roma
Country
Italy
Facility Name
Research Site
City
Acapulco
Country
Mexico
Facility Name
Research Site
City
Guadalajara
Country
Mexico
Facility Name
Research Site
City
México
Country
Mexico
Facility Name
Research Site
City
Veracruz
Country
Mexico
Facility Name
Research Site
City
Den Haag
Country
Netherlands
Facility Name
Research Site
City
Deurne
Country
Netherlands
Facility Name
Research Site
City
Gorinchem
Country
Netherlands
Facility Name
Research Site
City
Groningen
Country
Netherlands
Facility Name
Research Site
City
Lichtenvoorde (gld)
Country
Netherlands
Facility Name
Research Site
City
Losser
Country
Netherlands
Facility Name
Research Site
City
Poortvliet
Country
Netherlands
Facility Name
Research Site
City
Rotterdam
Country
Netherlands
Facility Name
Research Site
City
Wildervank
Country
Netherlands
Facility Name
Research Site
City
Zutphen
Country
Netherlands
Facility Name
Research Site
City
Cape Town
Country
South Africa
Facility Name
Research Site
City
Durban
Country
South Africa
Facility Name
Research Site
City
Johannesburg
Country
South Africa
Facility Name
Research Site
City
Parow
Country
South Africa
Facility Name
Research Site
City
Pretoria
Country
South Africa
Facility Name
Research Site
City
Umkomaas
Country
South Africa
Facility Name
Research Site
City
Witbank
Country
South Africa
Facility Name
Research Site
City
Alicante
Country
Spain
Facility Name
Research Site
City
Alzira (Valencia)
Country
Spain
Facility Name
Research Site
City
Barcelona
Country
Spain
Facility Name
Research Site
City
Cornellá de Llobregat (BCN)
Country
Spain
Facility Name
Research Site
City
Madrid
Country
Spain
Facility Name
Research Site
City
Sevilla
Country
Spain
Facility Name
Research Site
City
Göteborg
Country
Sweden
Facility Name
Research Site
City
Järfälla
Country
Sweden
Facility Name
Research Site
City
Lund
Country
Sweden
Facility Name
Research Site
City
Malmö
Country
Sweden
Facility Name
Research Site
City
Skene
Country
Sweden
Facility Name
Research Site
City
Stockholm
Country
Sweden
Facility Name
Research Site
City
Södertälje
Country
Sweden
Facility Name
Research Site
City
Umeå
Country
Sweden
Facility Name
Research Site
City
Addlestone
Country
United Kingdom
Facility Name
Research Site
City
Aylesbury
Country
United Kingdom
Facility Name
Research Site
City
Bath
Country
United Kingdom
Facility Name
Research Site
City
Bolton
Country
United Kingdom
Facility Name
Research Site
City
Bury St Edmonds
Country
United Kingdom
Facility Name
Research Site
City
Cookstown
Country
United Kingdom
Facility Name
Research Site
City
Coventry
Country
United Kingdom
Facility Name
Research Site
City
Ecclesfield
Country
United Kingdom
Facility Name
Research Site
City
Edinburgh
Country
United Kingdom
Facility Name
Research Site
City
Mortimer Reading
Country
United Kingdom
Facility Name
Research Site
City
Trowbridge
Country
United Kingdom
12. IPD Sharing Statement
Citations:
PubMed Identifier
21816980
Citation
Nauck MA, Del Prato S, Meier JJ, Duran-Garcia S, Rohwedder K, Elze M, Parikh SJ. Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial. Diabetes Care. 2011 Sep;34(9):2015-22. doi: 10.2337/dc11-0606. Epub 2011 Aug 4.
Results Reference
result
PubMed Identifier
23529570
Citation
Nauck M, del Prato S, Meier JJ, Duran-Garcia S, Rohwedder K, Elze M, Parikh SJ. [Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin]. Dtsch Med Wochenschr. 2013 Apr;138 Suppl 1:S6-15. doi: 10.1055/s-0032-1305283. Epub 2013 Mar 25. German.
Results Reference
derived
Links:
URL
http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_6111&studyid=289&filename=CSR-D1690C00004.pdf
Description
CSR-D1690C00004.pdf
Learn more about this trial
Efficacy and Safety of Dapagliflozin in Combination With Metformin in Type 2 Diabetes Patients
We'll reach out to this number within 24 hrs